.Pharmacolibrary.Drugs.ATC.M.M01BA02 .Pharmacolibrary.Drugs.ATC.M.M01BA02| name: | DipyrocetylAndCorticosteroids |
| ATC code: | M01BA02 | route: | oral |
| n-compartments | 1 |
Dipyrocetyl is an obscure or possibly obsolete analgesic/antipyretic compound; 'dipyrocetyl and corticosteroids' is a fixed-dose combination drug classified under ATC code M01BA02, indicated historically for inflammatory, rheumatic, and pain-related conditions. It is not widely approved or used in current clinical practice, and available data on its clinical use is extremely limited.
No published pharmacokinetic data found in literature or scientific databases for dipyrocetyl, or its combination with corticosteroids, for any population. The below parameters were estimated based on pharmacokinetic properties typical of non-steroidal anti-inflammatory drugs (such as salicylic acid derivatives) for reference adult individuals.
Krzyzanski, W, et al., & Jusko, WJ (2021). Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women. Journal of pharmacokinetics and pharmacodynamics 48(2) 261–272. DOI:10.1007/s10928-020-09730-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/33389521
Hamitouche, N, et al., & Laviolle, B (2017). Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. The AAPS journal 19(3) 727–735. DOI:10.1208/s12248-016-0041-9 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28083797
Werumeus Buning, J, et al., & van Beek, AP (2017). Pharmacokinetics of oral hydrocortisone - Results and implications from a randomized controlled trial. Metabolism: clinical and experimental 71 7–16. DOI:10.1016/j.metabol.2017.02.005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28521880